Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$6.74
-2.6%
$5.48
$3.79
$14.60
$337.69M-0.911.52 million shs711,469 shs
CorMedix Inc stock logo
CRMD
CorMedix
$10.86
-1.9%
$12.74
$3.61
$17.43
$736.58M1.581.38 million shs1.41 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$29.41
-1.1%
$25.77
$16.16
$31.80
$1.19B0.75224,944 shs353,025 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$9.15
-2.9%
$8.97
$6.50
$18.98
$968.85M0.8888,898 shs437,295 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-2.60%+16.01%+36.99%+47.48%+2.59%
CorMedix Inc stock logo
CRMD
CorMedix
-1.90%-3.21%-20.03%+41.59%+123.92%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.08%-4.51%+22.75%+70.10%+54.63%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-3.09%-2.14%+7.22%+16.04%-40.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
2.5795 of 5 stars
3.61.00.00.03.41.70.6
CorMedix Inc stock logo
CRMD
CorMedix
2.5906 of 5 stars
4.41.00.00.02.60.00.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
4.0506 of 5 stars
0.94.02.51.13.33.32.5
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.5092 of 5 stars
4.41.00.00.01.91.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
3.20
Buy$22.00226.41% Upside
CorMedix Inc stock logo
CRMD
CorMedix
2.88
Moderate Buy$17.1457.85% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-17.04% Downside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.89
Moderate Buy$21.29132.63% Upside

Current Analyst Ratings Breakdown

Latest CADL, CRMD, PAHC, and RCUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/30/2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$23.00
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/24/2025
CorMedix Inc stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $20.00
6/23/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
6/20/2025
CorMedix Inc stock logo
CRMD
CorMedix
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
$120K2,813.95N/AN/A$1.41 per share4.78
CorMedix Inc stock logo
CRMD
CorMedix
$43.47M16.94N/AN/A$1.40 per share7.76
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.17$2.11 per share13.91$6.34 per share4.64
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$258M3.76N/AN/A$5.30 per share1.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)
CorMedix Inc stock logo
CRMD
CorMedix
-$17.93M$0.2249.3711.55N/A20.81%22.57%17.02%8/13/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7837.7114.000.492.68%30.51%6.89%8/27/2025 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)

Latest CADL, CRMD, PAHC, and RCUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.14N/AN/AN/AN/AN/A
8/13/2025Q2 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.17N/AN/AN/A$29.88 millionN/A
8/12/2025Q2 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.17N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
-$0.24$0.13+$0.37$0.13N/AN/A
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/6/2025Q1 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.25$0.30+$0.05$0.30$38.90 million$39.08 million
5/6/2025Q1 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
N/AN/AN/AN/AN/A
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.63%N/A61.54%N/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A

Latest CADL, CRMD, PAHC, and RCUS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
0.01
4.64
4.64
CorMedix Inc stock logo
CRMD
CorMedix
N/A
4.21
3.99
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.09
5.37
5.37

Institutional Ownership

CompanyInstitutional Ownership
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
13.93%
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%

Insider Ownership

CompanyInsider Ownership
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
16.60%
CorMedix Inc stock logo
CRMD
CorMedix
5.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Candel Therapeutics, Inc. stock logo
CADL
Candel Therapeutics
6050.10 million41.79 millionOptionable
CorMedix Inc stock logo
CRMD
CorMedix
3067.82 million64.23 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500105.89 million95.72 millionOptionable

Recent News About These Companies

Arcus’ Quemliclustat Receives Orphan Drug Designation
Incyte, FDA, Sun Pharma and more—Chutes & Ladders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Candel Therapeutics stock logo

Candel Therapeutics NASDAQ:CADL

$6.74 -0.18 (-2.60%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.78 +0.04 (+0.52%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

CorMedix stock logo

CorMedix NASDAQ:CRMD

$10.86 -0.21 (-1.90%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$10.88 +0.03 (+0.23%)
As of 07/18/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$29.41 -0.32 (-1.08%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$29.44 +0.03 (+0.10%)
As of 07/18/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$9.15 -0.27 (-2.87%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$9.27 +0.12 (+1.32%)
As of 07/18/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.